145 related articles for article (PubMed ID: 2772867)
21. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
[TBL] [Abstract][Full Text] [Related]
22. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
23. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
24. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
25. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
26. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
27. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
28. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.
Klement P; Liao P; Hirsh J; Johnston M; Weitz JI
J Lab Clin Med; 1998 Sep; 132(3):181-5. PubMed ID: 9735923
[TBL] [Abstract][Full Text] [Related]
29. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Imura Y; Stassen JM; Collen D
J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394
[TBL] [Abstract][Full Text] [Related]
30. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
31. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
32. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Carteaux JP; Gast A; Tschopp TB; Roux S
Circulation; 1995 Mar; 91(5):1568-74. PubMed ID: 7867200
[TBL] [Abstract][Full Text] [Related]
33. Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin.
Matthiasson SE; Lindblad B; Bergqvist D
Haemostasis; 1995; 25(3):124-32. PubMed ID: 7607580
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
Kornowski R; Eldor A; Werber MM; Ezov N; Zwang E; Nimrod A; Chernine A; Finkelstein A; Panet A; Laniado S; Keren G
Coron Artery Dis; 1996 Dec; 7(12):903-9. PubMed ID: 9116933
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors.
Kaiser B; Markwardt F
Thromb Res; 1986 Sep; 43(6):613-20. PubMed ID: 3764808
[TBL] [Abstract][Full Text] [Related]
36. The Antithrombotic Effect of Recombinant Neorudin on Thrombi.
Liu YB; Zhang L; Zhou XC; Zhou Y; Liu Y; Zheng C; Xu X; Geng PP; Hao CH; Zhao ZY; Wu CT; Jin JD
Drug Des Devel Ther; 2022; 16():1667-1678. PubMed ID: 35677424
[TBL] [Abstract][Full Text] [Related]
37. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
[TBL] [Abstract][Full Text] [Related]
38. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Circulation; 1997 Aug; 96(3):769-77. PubMed ID: 9264481
[TBL] [Abstract][Full Text] [Related]
40. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Biemond BJ; Friederich PW; Levi M; Vlasuk GP; Büller HR; ten Cate JW
Circulation; 1996 Jan; 93(1):153-60. PubMed ID: 8616922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
